Since the dawn of human civilization, stories of fierce family rivalries have captured our interest. While the outcomes are less severe than the classic tales of family feuds during Tudor reign in England, there is increasing evidence for family infighting within the Src family protein-tyrosine kinases (SFKs) in immunity and allergic diseases. In mast cells activated via IgE receptor (FcεRI) aggregation, signaling is initiated by SFKs that phosphorylate immunoreceptor tyrosine-based activating motifs (ITAMs) to recruit downstream effectors that promote degranulation, lipid mediator, and cytokine/chemokine production. Although several SFKs participate, Lyn and Fyn are the key protagonists. Lyn initiates FcεRI signaling by phosphorylating ITAMs, leading to recruitment of Fyn and Syk kinases that promote mediator production and release (Metcalfe et al., [@B5]). However, Lyn also puts the brakes on mast cell activation by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit protein and lipid phosphatases. Lyn also promotes membrane recruitment and activation of C-terminal Src kinase (Csk) that phosphorylates SFKs to promote their return to an autoinhibited state (Gilfillan and Rivera, [@B2]).

In this issue of *Frontiers in Inflammation*, Pullen et al. ([@B6]) review important advances in our understanding of how activating, or ITAM-bearing IgG receptors signal via SFKs in mast cells. Not surprisingly, there are some similarities with FcεRI signaling mechanisms, and the Lyn vs. Fyn battle is maintained in these pathways. This review is also timely considering the emergence of activating IgG receptors as key inducers of anaphylaxis. Ryan and co-workers recently showed that Lyn suppresses IgG-mediated systemic anaphylaxis in mice (Falanga et al., [@B1]). In addition, seminal studies from the Bruhns lab implicate activating IgG receptor signaling in neutrophils, as a key source of platelet-activating factor (PAF) that triggers systemic anaphylaxis and airway inflammation (Jonsson et al., [@B3], [@B4]). These and other studies of IgG signaling in immune cells will undoubtedly spur new research and discoveries of new therapeutic targets and treatments for allergic diseases.
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